310 related articles for article (PubMed ID: 15761068)
1. Effect of opsonophagocytosis mediated by specific antibodies on the co-amoxiclav serum bactericidal activity against Streptococcus pneumoniae after administration of a single oral dose of pharmacokinetically enhanced 2000/125 mg co-amoxiclav to healthy volunteers.
Alou L; Aguilar L; Sevillano D; Giménez MJ; Laguna B; Echeverría O; Carcas A; Lubomirov R; Casal J; Prieto J
J Antimicrob Chemother; 2005 May; 55(5):742-7. PubMed ID: 15761068
[TBL] [Abstract][Full Text] [Related]
2. In vitro combined effect of co-amoxiclav concentrations achievable in serum after a 2000/125 mg oral dose, and polymorphonuclear neutrophils against strains of Streptococcus pneumoniae exhibiting decreased susceptibility to amoxicillin.
Amores R; Alou L; Giménez MJ; Sevillano D; Gómez-Lus ML; Aguilar L; Prieto J
Int J Antimicrob Agents; 2004 Jul; 24(1):79-82. PubMed ID: 15225866
[TBL] [Abstract][Full Text] [Related]
3. Bactericidal activity of amoxicillin against non-susceptible Streptococcus pneumoniae in an in vitro pharmacodynamic model simulating the concentrations obtained with the 2000/125 mg sustained-release co-amoxiclav formulation.
Sevillano D; Calvo A; Giménez MJ; Alou L; Aguilar L; Valero E; Carcas A; Prieto J
J Antimicrob Chemother; 2004 Dec; 54(6):1148-51. PubMed ID: 15489246
[TBL] [Abstract][Full Text] [Related]
4. Serum bactericidal activity and phagocytosis in host defence against Haemophilus ducreyi.
Lagergård T; Frisk A; Purvèn M; Nilsson LA
Microb Pathog; 1995 Jan; 18(1):37-51. PubMed ID: 7783597
[TBL] [Abstract][Full Text] [Related]
5. Oral pharmacokinetically enhanced co-amoxiclav 2000/125 mg, twice daily, compared with co-amoxiclav 875/125 mg, three times daily, in the treatment of community-acquired pneumonia in European adults.
Garau J; Twynholm M; Garcia-Mendez E; Siquier B; Rivero A;
J Antimicrob Chemother; 2003 Nov; 52(5):826-36. PubMed ID: 14563899
[TBL] [Abstract][Full Text] [Related]
6. Effect of polymorphonuclear neutrophils on serum bactericidal activity against Streptococcus pneumoniae after amoxicillin administration.
Gómez-Lus ML; Giménez MJ; Prieto J; Martín M; Frías J; Aguilar L
Eur J Clin Microbiol Infect Dis; 1998 Jan; 17(1):40-3. PubMed ID: 9512181
[TBL] [Abstract][Full Text] [Related]
7. Urine bactericidal activity against resistant Escherichia coli in an in vitro pharmacodynamic model simulating urine concentrations obtained after 2000/125 mg sustained-release co-amoxiclav and 400 mg norfloxacin administration.
Alou L; Aguilar L; Sevillano D; Giménez MJ; Cafini F; Valero E; Relaño MT; Prieto J
J Antimicrob Chemother; 2006 Apr; 57(4):714-9. PubMed ID: 16492718
[TBL] [Abstract][Full Text] [Related]
8. Opsonophagocytosis versus complement bactericidal killing as effectors following Neisseria meningitidis group C vaccination.
Gomez-Lus ML; Giménez MJ; Vázquez JA; Aguilar L; Anta L; Berrón S; Laguna B; Prieto J
Infection; 2003 Jan; 31(1):51-4. PubMed ID: 12590334
[TBL] [Abstract][Full Text] [Related]
9. Urinary concentrations and bactericidal activity against amoxicillin-nonsusceptible strains of Escherichia coli with single-dose, oral, sustained-release amoxicillin/clavulanic acid: a phase I, open-label, noncomparative clinical trial in healthy volunteers.
Ponte C; Gracia M; Giménez MJ; Aguilar L; Maín CM; Carpintero Y; Huelves L; Carcas A; del Prado G; Soriano F
Clin Ther; 2005 Jul; 27(7):1043-9. PubMed ID: 16154483
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamic studies of amoxicillin against Streptococcus pneumoniae: comparison of a new pharmacokinetically enhanced formulation (2000 mg twice daily) with standard dosage regimens.
Odenholt I; Cars O; Löwdin E
J Antimicrob Chemother; 2004 Dec; 54(6):1062-6. PubMed ID: 15563517
[TBL] [Abstract][Full Text] [Related]
11. Are beta-lactam breakpoints adequate to define non-susceptibility for all Haemophilus influenzae resistance phenotypes from a pharmacodynamic point of view?
Alou L; Giménez MJ; Sevillano D; Aguilar L; González N; Echeverría O; Torrico M; Coronel P; Prieto J
J Antimicrob Chemother; 2007 Apr; 59(4):652-7. PubMed ID: 17341471
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamic activity of ertapenem versus penicillin-susceptible and penicillin-non-susceptible Streptococcus pneumoniae using an in vitro model.
Zhanel GG; Derkatch S; Laing N; Noreddin AM; Hoban DJ
J Antimicrob Chemother; 2007 Jan; 59(1):144-7. PubMed ID: 17079238
[TBL] [Abstract][Full Text] [Related]
13. Aging reduces the functionality of anti-pneumococcal antibodies and the killing of Streptococcus pneumoniae by neutrophil phagocytosis.
Simell B; Vuorela A; Ekström N; Palmu A; Reunanen A; Meri S; Käyhty H; Väkeväinen M
Vaccine; 2011 Feb; 29(10):1929-34. PubMed ID: 21236231
[TBL] [Abstract][Full Text] [Related]
14. Antibacterial effects of amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae strains for which MICs are high, in an in vitro pharmacokinetic model.
MacGowan AP; Noel AR; Rogers CA; Bowker KE
Antimicrob Agents Chemother; 2004 Jul; 48(7):2599-603. PubMed ID: 15215115
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae.
Siquier B; Sánchez-Alvarez J; García-Mendez E; Sabriá M; Santos J; Pallarés R; Twynholm M; Dal-Ré R;
J Antimicrob Chemother; 2006 Mar; 57(3):536-45. PubMed ID: 16446376
[TBL] [Abstract][Full Text] [Related]
16. Impact of co-amoxiclav on polymorphonuclear granulocytes from chronic hemodialysis patients.
Cuffini AM; Tullio V; Giacchino F; Mandras N; Scalas D; Belardi P; Merlino C; Carlone NA
Am J Kidney Dis; 2001 Jun; 37(6):1253-9. PubMed ID: 11382696
[TBL] [Abstract][Full Text] [Related]
17. Clarithromycin mediated the expression of polymorphonuclear granulocyte response against streptococcus pneumoniae strains with different patterns of susceptibility and resistance to penicillin and clarithromycin.
Cuffini AM; Tullio V; Mandras N; Roana J; Scalas D; Banche G; Carlone NA
Int J Tissue React; 2002; 24(1):37-44. PubMed ID: 12013153
[TBL] [Abstract][Full Text] [Related]
18. Effects of human albumin and serum on the in vitro bactericidal activity of cefditoren against penicillin-resistant Streptococcus pneumoniae.
Sevillano D; Giménez MJ; Alou L; Aguilar L; Cafini F; Torrico M; González N; Echeverría O; Coronel P; Prieto J
J Antimicrob Chemother; 2007 Jul; 60(1):156-8. PubMed ID: 17483149
[TBL] [Abstract][Full Text] [Related]
19. Beta-lactam activity against penicillin-resistant Streptococcus pneumoniae strains exhibiting higher amoxicillin versus penicillin minimum inhibitory concentration values: an in vitro pharmacodynamic simulation.
Sevillano D; Aguilar L; Alou L; Giménez MJ; González N; Echeverría O; Torrico M; Valdes L; Coronel P; Prieto J
Chemotherapy; 2008; 54(2):84-90. PubMed ID: 18303256
[TBL] [Abstract][Full Text] [Related]
20. In vitro bactericidal activity of peak serum concentrations of co-amoxiclav, amoxicillin and vancomycin against methicillin-resistant Staphylococcus aureus.
Gómez-Lus ML; Prieto J; Giménez MJ; García M; Anta L; Aguilar L
Rev Esp Quimioter; 1999 Jun; 12(2):136-9. PubMed ID: 10562674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
